FAQ
1. How accessible are immune checkpoint inhibitors worldwide, and are cost barriers reducing?
ICIs are expensive and their access remains limited in low- and middle-income countries. Efforts including dose optimization and biosimilars aim to improve affordability and availability, but cost remains a significant barrier globally.
2. How long does it typically take for immune checkpoint inhibitors to show effects?
Responses to ICIs generally start becoming evident within a few weeks to a few months. Median time to best response often falls around 4 to 5 months, but some patients may show delayed or atypical responses, such as pseudoprogression, before improvement.
3. How does age influence eligibility and response to checkpoint inhibitor therapy?
ICIs can be used across a broad age range, including older adults. Age alone is not usually a barrier, but overall health and other medical conditions are considered to ensure safety and benefit.
Reference
1. Tanaka, A., & Sakaguchi, S. (2017). Regulatory T cells in cancer immunotherapy. Cell research, 27(1), 109-118.
2. Zhang, H., Dai, Z., Wu, W., et al. (2021). Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. Journal of Experimental & Clinical Cancer Research, 40(1), 184.
3. Cao, S., Li, J., Lu, J., et al. (2019). Mycobacterium tuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway. Cell death & disease, 10(2), 44.
4. Lipson, E. J., & Drake, C. G. (2011). Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clinical cancer research, 17(22), 6958-6962.
5. Khoja, L., Butler, M. O., Kang, S. P., et al. (2015). Pembrolizumab. Journal for immunotherapy of cancer, 3(1), 36.
6. Brahmer, J. R., Hammers, H., & Lipson, E. J. (2015). Nivolumab: targeting PD-1 to bolster antitumor immunity. Future oncology, 11(9), 1307-1326.
7. Shah, N. J., Kelly, W. J., Liu, S. V., et al. (2018). Product review on the Anti-PD-L1 antibody atezolizumab, 14(2), 269-276.
8. Tan, S., Liu, K., Chai, Y., et al. (2018). Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein & cell, 9(1), 135-139.
9. Sabbatino, F., Liguori, L., Pepe, S., et al. (2022). Immune checkpoint inhibitors for the treatment of melanoma. Expert opinion on biological therapy, 22(5), 563-576.
10. Herzberg, B., Campo, M. J., & Gainor, J. F. (2017). Immune checkpoint inhibitors in non‐small cell lung cancer. The oncologist, 22(1), 81-88.
11. Atkins, M. B., Clark, J. I., & Quinn, D. I. (2017). Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Annals of Oncology, 28(7), 1484-1494.
12. Poulose, J. V., & Kainickal, C. T. (2022). Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials. World Journal of Clinical Oncology, 13(5), 388.
13. Roviello, G., Catalano, M., Santi, R., et al. (2021). Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives. Cancers, 13(17), 4411.
14. Lee, V., Murphy, A., Le, D. T., et al. (2016). Mismatch repair deficiency and response to immune checkpoint blockade. The oncologist, 21(10), 1200-1211.
15. Rappold, P. M., Silagy, A. W., Kotecha, R. R., et al. (2021). Immune checkpoint blockade in renal cell carcinoma. Journal of surgical oncology, 123(3), 739-750.
16. Kumar, V., Chaudhary, N., Garg, M., et al. (2017). Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Frontiers in pharmacology, 8, 49.
17. Tyan, K., Baginska, J., Brainard, M., et al. (2021). Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 70(8), 2209-2221.
18. Mariniello, A., Borgeaud, M., Weiner, M., et al. (2025). Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: from bedside to bench and back. BioDrugs, 39(2), 215.
19. Erber, R., & Hartmann, A. (2020). Understanding PD-L1 testing in breast cancer: a practical approach. Breast care, 15(5), 481-490.
20. Park, H. J., Kim, K. W., Pyo, J., et al. (2020). Incidence of pseudoprogression during immune checkpoint inhibitor therapy for solid tumors: a systematic review and meta-analysis. Radiology, 297(1), 87-96.
21. Verma, V., Sprave, T., Haque, W., et al. (2018). A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. Journal for immunotherapy of cancer, 6(1), 128.
22. Vafaei, S., Zekiy, A. O., Khanamir, R. A., et al. (2022). Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. Cancer Cell International, 22(1), 2.
23. Willsmore, Z. N., Coumbe, B. G., Crescioli, S., et al. (2021). Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. European Journal of Immunology, 51(3), 544-556.
24. Liu, W., Zhang, L., Xiu, Z., et al. (2020). Combination of immune checkpoint inhibitors with chemotherapy in lung cancer. OncoTargets and therapy, 13(2020), 7229-724.
25. Voronova, V., Vislobokova, A., Mutig, K et al. (2022). Combination of immune checkpoint inhibitors with radiation therapy in cancer: a hammer breaking the wall of resistance. Frontiers in Oncology, 12, 1035884.
26. Zhao, J., Chen, Y., Ding, Z. Y., et al. (2019). Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment. Frontiers in pharmacology, 10, 1184.
27. LaRocca, C. J., & Warner, S. G. (2018). Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clinical and translational medicine, 7(1), 35.
28. Xu, J., Zheng, Q., Cheng, X., et al. (2021). Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma. Journal of nanobiotechnology, 19(1), 355.
29. Ma, G. L., & Lin, W. F. (2023). Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy. Military Medical Research, 10(1), 20.
30. Scognamiglio, G., De Chiara, A., Parafioriti, A., et al. (2019). Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors. British journal of cancer, 121(11), 979-982.
31. Lu, Y., Jin, J., Du, Q., et al. (2021). Multi-omics analysis of the anti-tumor synergistic mechanism and potential application of immune checkpoint blockade combined with lenvatinib. Frontiers in Cell and Developmental Biology, 9, 730240.
32. Zhao, Z., Xu, K., Jiang, Y., et al. (2024). The role of artificial intelligence in immune checkpoint inhibitor research: A bibliometric analysis. Human Vaccines & Immunotherapeutics, 20(1), 2429893.
33. Aggarwal, V., Workman, C. J., & Vignali, D. A. (2023). LAG-3 as the third checkpoint inhibitor. Nature immunology, 24(9), 1415-1422.
34. Attalla, K., Farkas, A. M., Anastos, H., et al. (2022, September). TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. In Urologic Oncology: Seminars and Original Investigations (Vol. 40, No. 9, pp. 403-406). Elsevier.
35. Thapa, B., Kato, S., Nishizaki, D., et al. (2024). OX40/OX40 ligand and its role in precision immune oncology. Cancer and Metastasis Reviews, 43(3), 1001-1013.
36. Yan, C., & Richmond, A. (2021). Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy. Molecular Cancer, 20(1), 146.
37. Li, X., Zhang, S., Guo, G., et al. (2022). Gut microbiome in modulating immune checkpoint inhibitors. EBioMedicine, 82, 104163.
38. Chennamadhavuni, A., Abushahin, L., Jin, N., et al. (2022). Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Frontiers in immunology, 13, 779691.
39. Hu, Z. (2017). The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy. Journal of Thoracic Disease, 9(11), 4226.
40. Barone, B., Calogero, A., Scafuri, L., et al. (2022). Immune checkpoint inhibitors as a neoadjuvant/adjuvant treatment of muscle-invasive bladder cancer: a systematic review. Cancers, 14(10), 2545.